title: Steady-state pharmacokinetics of galantamine are not affected by addition of memantine in healthy subjects.
abstract: To evaluate the effect of multiple doses of memantine on the pharmacokinetics of galantamine and to assess the safety and tolerability of galantamine with adjunctive memantine treatment, an open-label, single-center, drug interaction study was conducted in 16 healthy adults. Subjects received an 8-mg dose of galantamine extended release once daily during week 1 and a 16-mg dose of galantamine extended release once daily during week 2. During weeks 3 and 4, they received a 16-mg dose of galantamine extended release once daily and a 10-mg dose of memantine twice daily, except on days 1 and 2 of week 3, when memantine was given as 10 mg once daily. The pharmacokinetic profile and parameters of galantamine at steady state were similar after administration of a 16-mg dose of galantamine once daily alone and after administration with a 10-mg dose of memantine twice daily. Galantamine 16 mg once daily with adjunctive memantine 10 mg twice daily was well tolerated and safe in healthy subjects.
authors.affiliation: Johnson and Johnson Pharmaceutical Research and Development, LLC, 1125 Trenton-Harbourton Road, PO Box 200, Titusville, NJ 08560, USA.
authors.forename: Caiping
authors.initials: C
authors.lastname: Yao
authors.forename: Arash
authors.initials: A
authors.lastname: Raoufinia
authors.forename: Michael
authors.initials: M
authors.lastname: Gold
authors.forename: Jeffrey S
authors.initials: JS
authors.lastname: Nye
authors.forename: Steven
authors.initials: S
authors.lastname: Ramael
authors.forename: Mukund
authors.initials: M
authors.lastname: Padmanabhan
authors.forename: Yolande
authors.initials: Y
authors.lastname: Walschap
authors.forename: Tom
authors.initials: T
authors.lastname: Verhaeghe
authors.forename: Qinying
authors.initials: Q
authors.lastname: Zhao
mesh_terms: D000328:Adult; D019540:Area Under Curve; D002800:Cholinesterase Inhibitors / Q000008:administration & dosage / Q000009:adverse effects / Q000493:pharmacokinetics*; D003692:Delayed-Action Preparations; D004347:Drug Interactions; D005260:Female; D005702:Galantamine / Q000008:administration & dosage / Q000009:adverse effects / Q000493:pharmacokinetics*; D006207:Half-Life; D006801:Humans; D008297:Male; D008559:Memantine / Q000009:adverse effects / Q000493:pharmacokinetics / Q000494:pharmacology*; D008875:Middle Aged; D016194:Receptors, N-Methyl-D-Aspartate / Q000037:antagonists & inhibitors*
chemical_list: D002800:Cholinesterase Inhibitors; D003692:Delayed-Action Preparations; D016194:Receptors, N-Methyl-D-Aspartate; D005702:Galantamine; D008559:Memantine